• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ICU Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/7/25 4:11:06 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care
    Get the next $ICUI alert in real time by email
    icui-20250807
    falseICU MEDICAL INC/DE000088398400008839842025-08-072025-08-07

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported) August 7, 2025

    ICU MEDICAL, INC.

    (Exact name of registrant as specified in its charter)
    Delaware001-3463433-0022692
    (State or other jurisdiction
    of incorporation)
    (Commission File Number)
    (IRS Employer
    Identification No.)
    951 Calle Amanecer,San Clemente,California92673
    (Address of principal executive offices)(Zip Code)

    (949) 366-2183
    Registrant's telephone number, including area code

    N/A
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading SymbolName of each exchange on which registered
    Common stock, par value $0.10 per shareICUIThe Nasdaq Stock Market LLC
    (Global Select Market)
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





    Item 2.02. Results of Operations and Financial Condition

        On August 7, 2025, ICU Medical, Inc. issued a press release announcing its financial results for the second quarter of 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in Item 2.02 by reference.
         
    Item 9.01. Financial Statements and Exhibits.
    (d)Exhibits
    99.1
    Press release, dated August 7, 2025 announcing ICU Medical, Inc.'s second quarter 2025 earnings.
    104Cover Page Interactive Data File (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
        ICU MEDICAL, INC.
    Date: August 7, 2025  By: /s/ Brian M. Bonnell
       Brian M. Bonnell
       Chief Financial Officer and Treasurer


    Get the next $ICUI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICUI

    DatePrice TargetRatingAnalyst
    8/15/2025$145.00Overweight
    Piper Sandler
    3/12/2025$205.00 → $197.00Outperform → Strong Buy
    Raymond James
    12/11/2024$200.00Hold → Buy
    Jefferies
    10/14/2024$183.00Hold
    Jefferies
    6/21/2024Hold
    Needham
    6/17/2024$135.00Mkt Perform → Outperform
    Raymond James
    11/8/2022Outperform → Mkt Perform
    Raymond James
    2/28/2022$286.00 → $265.00Outperform
    Raymond James
    More analyst ratings

    $ICUI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Jain Vivek bought $2,474,375 worth of shares (21,929 units at $112.84), increasing direct ownership by 20% to 130,149 units (SEC Form 4)

    4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

    8/14/25 7:07:45 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    SEC Filings

    View All

    SEC Form S-8 filed by ICU Medical Inc.

    S-8 - ICU MEDICAL INC/DE (0000883984) (Filer)

    8/8/25 4:05:53 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by ICU Medical Inc.

    10-Q - ICU MEDICAL INC/DE (0000883984) (Filer)

    8/7/25 4:17:58 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ICU MEDICAL INC/DE (0000883984) (Filer)

    8/7/25 4:11:06 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER issued to ICU MEDICAL INC

    Submission status for ICU MEDICAL INC's drug POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (SUPPL-8) with active ingredient POTASSIUM CHLORIDE; SODIUM CHLORIDE has changed to 'Approval' on 05/15/2023. Application Category: ANDA, Application Number: 078446, Application Classification: Labeling

    5/17/23 4:40:03 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Jain Vivek bought $2,474,375 worth of shares (21,929 units at $112.84), increasing direct ownership by 20% to 130,149 units (SEC Form 4)

    4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

    8/14/25 7:07:45 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    VP, General Counsel Sanzone Virginia Ruth sold $93,537 worth of shares (700 units at $133.62), decreasing direct ownership by 10% to 6,386 units (SEC Form 4)

    4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

    5/30/25 2:34:28 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Voigtlander Christian B. exercised 11,115 shares at a strike of $96.83 and sold $1,288,371 worth of shares (9,930 units at $129.75), increasing direct ownership by 24% to 6,088 units (SEC Form 4)

    4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

    5/28/25 12:00:55 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance

    SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. Second Quarter 2025 Results Second quarter 2025 revenue was $548.9 million, as compared to $596.5 million in the same period in the prior year. GAAP gross profit for the second quarter of 2025 was $208.1 million, as compared to $207.4 million in the same period in the prior year. GAAP gross margin for the second quarter of 2025 was 38%, as compared to 35% in the same period in the prior year. GAAP net income for the second quarter of 202

    8/7/25 4:05:00 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Announces Time of Second Quarter 2025 Earnings Conference Call

    SAN CLEMENTE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2025 earnings release and conference call. The Company will release its second quarter 2025 results on Thursday, August 7, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, August 7, 2025. The call can be accessed at (800) 267-6316, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's

    7/24/25 8:30:00 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Announces First Quarter 2025 Results

    SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025. First Quarter 2025 Results First quarter 2025 revenue was $604.7 million, as compared to $566.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2025 was $210.1 million, as compared to $185.2 million in the same period in the prior year. GAAP gross margin for the first quarter of 2025 was 35%, as compared to 33% in the same period in the prior year. GAAP net loss for the first quarter of 2025 was $(15.

    5/8/25 4:05:00 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on ICU Medical with a new price target

    Piper Sandler initiated coverage of ICU Medical with a rating of Overweight and set a new price target of $145.00

    8/15/25 8:19:19 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical upgraded by Raymond James with a new price target

    Raymond James upgraded ICU Medical from Outperform to Strong Buy and set a new price target of $197.00 from $205.00 previously

    3/12/25 7:28:15 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical upgraded by Jefferies with a new price target

    Jefferies upgraded ICU Medical from Hold to Buy and set a new price target of $200.00

    12/11/24 7:52:44 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Leadership Updates

    Live Leadership Updates

    View All

    Carlyle Group and WP Carey Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Nov. 27, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Thursday, November 30: Carlyle Group Inc. (NASD: CG) will replace ICU Medical Inc. (NASD: ICUI) in the S&P MidCap 400. ICU Medical will replace PacWest Bancorp (NASD: PACW) in the S&P SmallCap 600. Banc of California Inc. (NYSE:BANC) is acquiring PacWest Bancorp in a deal expected to be completed soon, pending final closing conditions. Post-merger, Banc of California will remain in the S&P SmallCap 600. ICU Medical is more representative of the small-cap market space.WP Carey Inc. (NYSE: WPC) will replace Worthingt

    11/27/23 6:28:00 PM ET
    $AVTA
    $BANC
    $CG
    Finance: Consumer Services
    Finance
    Major Banks
    Investment Managers

    $ICUI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ICU Medical Inc.

    SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)

    11/12/24 3:44:43 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ICU Medical Inc.

    SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)

    11/8/24 10:34:33 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by ICU Medical Inc.

    SC 13D/A - ICU MEDICAL INC/DE (0000883984) (Subject)

    7/18/24 7:06:07 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Financials

    Live finance-specific insights

    View All

    ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance

    SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. Second Quarter 2025 Results Second quarter 2025 revenue was $548.9 million, as compared to $596.5 million in the same period in the prior year. GAAP gross profit for the second quarter of 2025 was $208.1 million, as compared to $207.4 million in the same period in the prior year. GAAP gross margin for the second quarter of 2025 was 38%, as compared to 35% in the same period in the prior year. GAAP net income for the second quarter of 202

    8/7/25 4:05:00 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Announces Time of Second Quarter 2025 Earnings Conference Call

    SAN CLEMENTE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2025 earnings release and conference call. The Company will release its second quarter 2025 results on Thursday, August 7, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, August 7, 2025. The call can be accessed at (800) 267-6316, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's

    7/24/25 8:30:00 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Announces First Quarter 2025 Results

    SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025. First Quarter 2025 Results First quarter 2025 revenue was $604.7 million, as compared to $566.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2025 was $210.1 million, as compared to $185.2 million in the same period in the prior year. GAAP gross margin for the first quarter of 2025 was 35%, as compared to 33% in the same period in the prior year. GAAP net loss for the first quarter of 2025 was $(15.

    5/8/25 4:05:00 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care